We develop, manufacture and promote modern medicines, focusing efforts on increasing the effectiveness and improving the safety profile of therapy for the most important diseases, including socially significant ones
>200 drug products in the portfolio
>80% are included in the list of vital and essential drugs (VED list)
60 drugs — MA applications under review
30 drugs — at various phases of clinical studies
80 drugs — at various phases of development
SIGNIFICANCE
By creating innovative drugs, we work with critical challenges, making a significant contribution to medical science, practice and manufacturing.
We are interested in creating radical changes for the better, finding unique and considerable solutions.
ACHIEVEMENTS
We are able to quickly respond to challenges and focus on goals. We are proud of the achievements of the company and our team, but we never stop. Our main achievements are always ahead.
CARE FOR THE FUTURE
We create the future by making people's lives and the world around us better. Our contribution to the development of local communities and the improvement of the environment is important to us.
TOP MANAGEMENT
Dr. Petr Belyy
Chairman of the Board, Scientific supervisor
Academic degree of Candidate of medical sciences (MD–PhD).
The theme of the scientific research is «Polymorphism of the gene CYP2C19 and clinical of efficacy PPIs (proton pump inhibitors)».
The author of numerous books and publications in the field of clinical medicine and pharmacology.
Since 1994 in the pharmaceutical industry.
Mr. Ilya Troshin
CEO, founder
Since 1994 in the financial industry.
Commercial and investment banking
Project financing
Since 2010 in the pharmaceutical industry.
Experience and professional activity:
Management of international R&D investments
Management of Company’s international investments and finances
